1 2 G Protein Pathways - Part C, Effector Mechanisms
I had a little bit too much carbohydrate that fed whatevers was living in there
Additionally, current gaps in the literature are identified to inform future research aimed at clarifying safety, patient selection, and the appropriateness of potential combined therapeutic strategies
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]